Corfluvec component 2

Corfluvec component 2 is one part of a two-component intranasal COVID-19 vaccine called Corfluvec. It is currently being investigated in a Phase 1 clinical trial in healthy adults (18-60 years old) to evaluate its safety and immunogenicity for the prevention of COVID-19. The trial structure involves administering the two vaccine components separately and then together with a 21-day interval as part of a complete vaccine regimen. The study is designed to include 200 participants and has a duration of about 6.5 months per participant. Specific details about the exact nature or composition of component 2, its mechanism of action, the specific developers, or manufacturers are not available in the provided information.